Clinical Trial Update: The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus [Phase 4]

View source ↗

Summary

Phase 4 trial comparing faster insulin aspart (Fiasp) to conventional insulin aspart (NovoLog) for correction bolus in Type 1 Diabetes Mellitus; the status is U…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)
• NovoLog (insulin aspart)

Snippet

Sponsor: Mountain Diabetes and Endocrine Center | Conditions: Type 1 Diabetes Mellitus | Phase 4 | Status: UNKNOWN